CXXI heads into the final trading day of April under notable pressure — a 24% weekly loss on paper-thin volume, accompanied by a sudden and sharp build in short positioning that stands out against the stock's normally quiet borrow market.
The most striking development this week is in the lending data. Short interest has climbed roughly 45% over the past week to about 12,092 shares estimated short, equivalent to just 0.01% of the free float. In raw terms that is a tiny absolute level, but the speed of the build is hard to ignore: the month-on-month percentage change is enormous, driven by a near-zero base at end-March when only a handful of shares were short. What makes the setup more interesting is that availability has opened up sharply — currently running at over 2,100% of short interest, meaning the lending pool is anything but constrained. Cost to borrow has eased back from a recent peak near 10.7% in early April to around 6.2% now, a move of roughly 37% in a week. Availability is very loose relative to the stock's own history; the 52-week high utilization reading was 99.87%, suggesting there have been moments when demand for borrows completely swamped supply. Today's reading of 45% utilization is well below that extreme, but the jump from near-zero earlier this month is notable. The borrow market is telling a story of fresh short demand meeting adequate supply — no squeeze pressure, but an accelerating lean to the downside.
The ORTEX short score reinforces that shift. It has climbed from around 30–31 through mid-April to roughly 45 as of April 28 — not extreme in absolute terms, but a meaningful acceleration over just a few sessions. The score's jump from 37 on April 24 to 45 by April 28 tracks almost exactly with the spike in utilization from 21% to 45% over the same two days, suggesting the short build is a fresh and deliberate move rather than a residual position.
The broader peer group offers little comfort. Close peers JUSH.F and CL fell 21% and 16% respectively on the week, while WEED lost 21%. TRUL was the outlier, gaining nearly 19%. The cannabis sector's struggles are clearly not idiosyncratic to C21 — the whole cohort is under pressure. CXXI's 24% decline, however, is toward the worse end of even that stressed peer set.
Ownership is concentrated. AdvisorShares holds around 15% of shares, with their position last reported as a new build as of March 31. Nomura holds roughly 8.6%, though that filing is over a year old. Insider data is stale — the most recent recorded trade dates to May 2024, a director purchase of 50,000 shares at CAD 0.41. With the stock now trading at CAD 0.38, that buyer is modestly underwater. There is no fresh insider signal to read into the current decline.
Earnings history offers thin but mixed evidence. The November 2025 print saw the stock fall over 20% the next day and drop nearly 15% over five sessions. The most recent February 2026 event was more benign, with a 3.8% move higher. The next scheduled event is June 24. Between now and then, the story is less about what C21 will report and more about whether the fresh short build of the past two weeks reflects something specific — or simply sector-wide pessimism dragging a thinly traded micro-cap lower with the rest of the cannabis cohort.
See the live data behind this article on ORTEX.
Open CXXI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
